Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - GENEREX BIOTECHNOLOGY CORP | ex31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - GENEREX BIOTECHNOLOGY CORP | ex31_1.htm |
| 10-K/A - FORM 10-K/A - GENEREX BIOTECHNOLOGY CORP | gnbt073119form10ka.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K/A of Generex Biotechnology Corporation (the “Company”) for the year ended July 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Joseph Moscato, Chief Executive Officer, and Mark Corrao, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: June 29th, 2020
| /s/ Joseph Moscato | |
| Joseph Moscato | |
| President & Chief Executive Officer | |
| /s/ Mark Corrao | |
| Mark Corrao | |
| Chief Financial Officer |